TABLE 1.
Main characteristics of the studies included in the meta-analysis.
| Author | Year | Tumor | Phase | Line | INT | N | ORR | DCR | mPFS |
|
|
|||||||||
| (%) | (%) | (mo.) | |||||||
| Robert Motzer | 2021 | Advanced RCC | III | 1L | L + K | 355 | 71.0 | 90.2 | 23.9 |
| Hyun Cheol Chung | 2021 | Advanced GC | II | 3L | L + K | 31 | 10.0 | 48.0 | 2.5 |
| Luis Villanueva | 2021 | Advanced CHOL | II | 2L | L + K | 31 | 10.0 | 68.0 | 6.1 |
| Carlos Gomez-Roca | 2021 | Advanced colorectal | II | 3L | L + K | 32 | 22.0 | 47.0 | 2.3 |
| Chung-Han Lee | 2020 | Metastatic ccRCC | II | ≥2L | L + K | 104 | 51.0 | 91.0 | 11.7 |
| Akihito Kawazoe | 2020 | Advanced GC | II | 1/2L | L + K | 29 | 69.0 | 100.0 | 7.1 |
| Bryan R Haugen | 2020 | RR-DTC | II | ≥2L | L + K | 30 | 62.0 | 97.0 | NE |
| Vicky Makker | 2020 | Advanced UCEC | Ib/II | ≥2L | L + K | 94 | 38.3 | 78.7 | 7.4 |
| Matthew H. Taylor | 2020 | Advanced SKCM | Ib/II | ≥2L | L + K | 21 | 48.0 | 81.0 | 5.5 |
| Ana Arance | 2020 | Advanced SKCM | Ib/II | ≥2L | L + K | 103 | 21.4 | 65.0 | 4.2 |
| Richard S. Finn | 2020 | Unresectable HCC | Ib | 1L | L + K | 104 | 46.0 | 88.0 | 9.3 |
| Qi Li | 2020 | Unresectable HCC | NE | 1L | L + PD-1 inhibitors | 22 | 50.0 | 90.9 | 12.1 |
| Masatoshi Kudo | 2020 | Unresectable HCC | Ib | 1L | L + O | 24 | 66.7 | 91.7 | 7.4 |
| Matthew H. Taylor | 2020 | Advanced HNSC | Ib/II | ≥2L | L + K | 22 | 46.0 | 91.0 | 4.7 |
| Matthew H. Taylor | 2020 | Advanced NSCLC | Ib/II | ≥2L | L + K | 21 | 33.0 | 81.0 | 5.9 |
| Zarnie Lwin | 2020 | Advanced ovarian | II | 4L | L + K | 31 | 32.3 | 74.2 | NE |
| Zarnie Lwin | 2020 | Advanced TNBC | II | 2/3L | L + K | 31 | 29.0 | 58.1 | NE |
| Jianzhen Lin | 2020 | Refractory CHOL | NE | ≥2L | L + K | 32 | 25.0 | 78.1 | 4.9 |
| Matthew H. Taylor | 2020 | Advanced BLCA | Ib/II | ≥2L | L + K | 20 | 25.0 | 70.0 | 5.4 |
| Zarnie Lwin | 2020 | Advanced GBM | II | 2L | L + K | 31 | 16.1 | 58.1 | NE |
INT, intervention; N, patient population numbers; ORR, objective response rate; DCR, disease control rate; mPFS, median progression free survival; PD-1, programmed cell death 1; L, lenvatinib; K, pembrolizumab; O, nivolumab; BLCA, bladder urothelial carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ccRCC, clear cell renal cell carcinoma; GC, gastric cancer; HNSC, head and neck squamous cell carcinoma; GBM, glioblastoma multiforme; HCC, hepatocellular carcinoma, NSCLC, non-small-cell lung cancer; RR-DTC, radioiodine-refractory differentiated thyroid carcinoma; RCC, renal cell carcinoma; SKCM, skin cutaneous melanoma; TNBC, triple-negative breast carcinoma; UCEC, uterine corpus endometrial carcinoma.